27 results for "Martin Forster"
Showing 1–20 · 0.49 seconds · RSS
-
Journal Article
Public health interventions: evaluating the economic evaluations
Recent years have witnessed much progress in the incorporation of economic considerations into the evaluation of public health interventions. In England, the Centre for Public Health Excellence within the National Institute for Health and Care Excellence works to develop guidance for preventing…
-
Journal Article
Clinical Significance of Parent Training for Children with Conduct Problems
While there is a strong evidence base for behavioral parent training in the treatment of child conduct problems, the clinical impact is less well known. Metaanalyses report effect sizes in the medium range, but the common practice of reporting “small,” “medium,” and “large” effects can be…
Also available at: DOAJ
-
Journal Article
Reach and predictors of effects during nation-wide dissemination of the universal parenting program All Children in Focus
Abstract Background Parenting programs have the potential to improve population health, if widely disseminated. However, wide-scale dissemination is challenging. Also, more knowledge is needed of whether parenting programs are effective for the variability of families in the general population…
-
Journal Article
Parent training tailored for parents with ADHD: a randomized controlled trial
Abstract Background Parents who themselves have Attention-Deficit/Hyperactivity Disorder (ADHD) tend to benefit less from conventional parent training (PT) interventions than parents without ADHD, reporting suboptimal effects on both parenting-related outcomes and child externalizing or…
-
Journal Article
Value-adaptive clinical trial designs for efficient delivery of publicly funded trials - a discussion of methods, case studies, opportunities and challenges
Abstract Background Value-adaptive designs for clinical trials are a novel set of emerging methods for delivering greater value for clinical research. There is increasing interest in using them within publicly funded health systems. A value-adaptive design permits ‘in progress’ changes to be made…
-
Journal Article
The performance of a Bayesian value-based sequential clinical trial design in the presence of an equivocal cost-effectiveness signal: evidence from the HERO trial
Abstract Background There is increasing interest in the capacity of adaptive designs to improve the efficiency of clinical trials. However, relatively little work has investigated how economic considerations – including the costs of the trial – might inform the design and conduct of adaptive…
-
Journal Article
The development and validation of a risk score : LUng Cancer Improved Decisions (LUCID)
Less than 20% of patients diagnosed with advanced lung cancer will survive beyond five years and half of these will suffer a serious adverse event (SAE) caused by systemic anticancer therapy (SACT) resulting in a hospital attendance. We applied counterfactual prediction models, grounded in causal…
-
Journal Article
Protocol for the development and validation of a risk score to predict risk of adverse events associated with systemic anti-cancer treatment in late-stage lung cancer: Lung Cancer Improved Decisions (LUCID)
Abstract Background Less than 20% of patients diagnosed with advanced lung cancer will survive beyond five years and half of these will suffer a serious adverse event (SAE) caused by systemic anticancer therapy (SACT) that will result in a hospital attendance. As multiple different SACT treatments…
-
Journal Article
Entrectinib-Induced Myocarditis and Acute Heart Failure Responding to Steroid Treatment: A Case Report
A 72-year-old man presented to his general practitioner with worsening dyspnea and was diagnosed with having recurrent ROS1-positive stage IIIB NSCLC 8 years after initial diagnosis and radical treatment for early stage disease. He was subsequently started on entrectinib but required hospital…
-
Journal Article
Protocol for the EACH trial: a multicentre phase II study evaluating the safety and antitumour activity of the combination of avelumab, an anti-PD-L1 agent, and cetuximab, as any line treatment for patients with recurrent/metastatic head and neck squamous cell cancer (HNSCC) in the UK
Introduction Head and neck cancer is the eighth most common cancer in the UK. Current standard of care treatment for patients with recurrent/metastatic squamous cell head and neck carcinoma (HNSCC) is platinum-based chemotherapy combined with the anti-epidermal growth factor receptor (anti-EGFR)…
-
Journal Article
Phase I trial of WEE1 inhibition with chemotherapy and radiotherapy as adjuvant treatment, and a window of opportunity trial with cisplatin in patients with head and neck cancer: the WISTERIA trial protocol
Introduction Patients with head and neck squamous cell carcinoma with locally advanced disease often require multimodality treatment with surgery, radiotherapy and/or chemotherapy. Adjuvant radiotherapy with concurrent chemotherapy is offered to patients with high-risk pathological features…
-
Journal Article
Prospective analysis of 895 patients on a UK Genomics Review Board
Background The increasing frequency and complexity of cancer genomic profiling represents a challenge for the oncology community. Results from next-generation sequencing–based clinical tests require expert review to determine their clinical relevance and to ensure patients are stratified…
-
Journal Article
COVID-19 in cancer patients on systemic anti-cancer therapies: outcomes from the CAPITOL (COVID-19 Cancer PatIenT Outcomes in North London) cohort study
Background: Patients with cancer are hypothesised to be at increased risk of contracting COVID-19, leading to changes in treatment pathways in those treated with systemic anti-cancer treatments (SACT). This study investigated the outcomes of patients receiving SACT to assess whether they were at…
-
Journal Article
Eftilagimod Alpha (a Soluble LAG-3 Protein) Combined With Pembrolizumab in Second-Line Metastatic NSCLC Refractory to Anti–Programmed Cell Death Protein 1/Programmed Death-Ligand 1-Based Therapy: Final Results from a Phase 2 Study
Introduction: Eftilagimod alpha (efti), a soluble lymphocyte activation gene-3 protein, triggers antigen-presenting cell and T-cell (CD4+ and CD8+) activation and helps overcome resistance to programmed cell death protein 1 or programmed cell death-ligand 1 (PD-(L)1) inhibitors. We assessed efti…
-
Journal Article
CompARE: study protocol for a phase III randomised controlled platform trial comparing alternative regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer
Abstract Background Patients with intermediate and high-risk oropharyngeal cancer (OPC) have poorer response to standard treatment and poorer overall survival compared to low-risk OPC. CompARE is designed to test alternative approaches to intensified treatment for these patients to improve…
-
Journal Article
Predicting progression-free survival after systemic therapy in advanced head and neck cancer: Bayesian regression and model development
Background: Advanced head and neck squamous cell carcinoma (HNSCC) is associated with a poor prognosis, and biomarkers that predict response to treatment are highly desirable. The primary aim was to predict progression-free survival (PFS) with a multivariate risk prediction model. Methods…